New Use of Staurosporine Derivatives

Abstract

This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.

1 . A method of treating mastocytosis, which comprises administering a therapeutically effective amount of the compound of formula (VII) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         to a human patient suffering from mastocytosis. 
       
     
     
         2 . A method according to  claim 1 , wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles. 
     
     
         3 . A method according to  claim 1 , wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily. 
     
     
         4 . A method according to  claim 1 , wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily. 
     
     
         5 . A method according to  claim 1 , wherein the compound of formula VII, is administered three times a day, for a total dose of 225 mg daily. 
     
     
         6 . A method according to  claim 1 , wherein the compound of formula VII is administered orally. 
     
     
         7 . A method according to  claim 1 , wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 
     
     
         8 . A method according to  claim 1 , wherein up to 150 mg per day of the compound of formula VII is administered. 
     
     
         9 . A method according to  claim 4 , wherein the compound of formula VII is administered orally. 
     
     
         10 . A method according to  claim 9 , wherein the compound of formula VII is administered as a microemulsion. 
     
     
         11 . A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of the compound of formula (VII) 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         to a patient suffering from mastocytosis with resistance to imatinib. 
       
     
     
         12 . A method according to  claims 11 , wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles. 
     
     
         13 . A method according to  claim 11 , wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily. 
     
     
         14 . A method according to  claim 11 , wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily. 
     
     
         15 . A method according to  claim 11 , wherein the patient has KIT tyrosine kinase receptor with a D816V mutation. 
     
     
         16 . A method according to  claim 11 , wherein the compound of formula VII is administered orally. 
     
     
         17 . A method according to  claim 11 , wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 
     
     
         18 . A method according to  claim 11 , wherein up to 150 mg per day of the compound of formula VII is administered. 
     
     
         19 . A method according to  claim 14 , wherein the compound of formula VII is administered orally. 
     
     
         20 . A method according to  claim 19 , wherein the compound of formula VII is administered as a microemulsion.